View Future GrowthJeonjinbio 과거 순이익 실적과거 기준 점검 2/6Jeonjinbio은 연평균 39.2%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 0.3% 감소했습니다. 매출은 연평균 29.4%의 비율로 증가했습니다. Jeonjinbio의 자기자본이익률은 0.1%이고 순이익률은 0.1%입니다.핵심 정보39.16%순이익 성장률42.33%주당순이익(EPS) 성장률Chemicals 산업 성장률13.95%매출 성장률29.38%자기자본이익률0.097%순이익률0.12%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트분석 기사 • Mar 14We Think Jeonjinbio's (KOSDAQ:110020) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) strong earnings didn't offer...Reported Earnings • May 19First quarter 2024 earnings released: ₩36.00 loss per share (vs ₩169 loss in 1Q 2023)First quarter 2024 results: ₩36.00 loss per share (improved from ₩169 loss in 1Q 2023). Revenue: ₩4.41b (up 84% from 1Q 2023). Net loss: ₩282.3m (loss narrowed 76% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.Reported Earnings • Nov 14Third quarter 2020 earnings released: ₩120 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: ₩1.08b (up 8.9% from 3Q 2019). Net loss: ₩577.5m (loss narrowed 7.2% from 3Q 2019).모든 업데이트 보기Recent updatesNew Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.9b (US$9.68m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩14.9b market cap, or US$9.68m). Minor Risk Profit margins are more than 30% lower than last year (0.1% net profit margin).Valuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₩2,450, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.공시 • Mar 11Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,848, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 54% over the past three years.분석 기사 • Nov 21Returns At Jeonjinbio (KOSDAQ:110020) Are On The Way UpIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...New Risk • Oct 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩24.9b market cap, or US$17.5m).분석 기사 • Sep 03The Price Is Right For Jeonjinbio Co., Ltd. (KOSDAQ:110020) Even After Diving 28%Unfortunately for some shareholders, the Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has dived 28% in the last...분석 기사 • Jul 24Returns On Capital Are Showing Encouraging Signs At Jeonjinbio (KOSDAQ:110020)There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,260, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 19% over the past three years.New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩30.9b market cap, or US$22.7m).Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,630, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.New Risk • May 23New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 25% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Market cap is less than US$100m (₩20.3b market cap, or US$14.8m).분석 기사 • Mar 14We Think Jeonjinbio's (KOSDAQ:110020) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) strong earnings didn't offer...공시 • Mar 06Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South KoreaValuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩2,885, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 48% over the past three years.분석 기사 • Jan 07Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) Price In Tune With RevenuesWhen close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.6x...New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩21.3b market cap, or US$14.5m).New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩24.5b market cap, or US$17.0m).분석 기사 • Oct 25There's Been No Shortage Of Growth Recently For Jeonjinbio's (KOSDAQ:110020) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...공시 • Jun 15Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun.Dabin BNS Co., Ltd. agreed to acquire 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun for KRW 22 billion on October 13, 2023. The transaction is expected to close on November 24, 2023. As on November 24, 2023, the transaction is expected to close on December 15, 2023. The transaction is expected to complete on March 28, 2024. The transaction is expected to complete on May 9, 2024. The transaction is expected to complete on May 30, 2024. As of May 30, 2024, the transaction is expected to close on June 5, 2024. The transaction is expected to complete on June 07, 2024. As of June 7, 2024, the transaction is expected to close on June 13, 2024.Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun on June 13, 2024.분석 기사 • Jun 07With A 38% Price Drop For Jeonjinbio Co., Ltd. (KOSDAQ:110020) You'll Still Get What You Pay ForThe Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has fared very poorly over the last month, falling by a...New Risk • Jun 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩33.4b market cap, or US$24.4m).Reported Earnings • May 19First quarter 2024 earnings released: ₩36.00 loss per share (vs ₩169 loss in 1Q 2023)First quarter 2024 results: ₩36.00 loss per share (improved from ₩169 loss in 1Q 2023). Revenue: ₩4.41b (up 84% from 1Q 2023). Net loss: ₩282.3m (loss narrowed 76% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.공시 • May 09Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million.Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million. Security Name: Shares Security Type: Common Stock Securities Offered: 188,679 Price\Range: KRW 5300 Transaction Features: Subsequent Direct Listing분석 기사 • Apr 03Shareholders Should Be Pleased With Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) PriceJeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) price-to-sales (or "P/S") ratio of 3.7x may look like a poor investment...New Risk • Oct 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩63.6b market cap, or US$46.8m).New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩40.4b market cap, or US$30.5m).New Risk • Jul 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.4b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₩37.0b market cap, or US$29.3m).분석 기사 • Apr 13Is Jeonjinbio (KOSDAQ:110020) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Mar 07New 90-day high: ₩12,700The company is up 2.0% from its price of ₩12,500 on 07 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period.분석 기사 • Feb 19If You Had Bought Jeonjinbio (KOSDAQ:110020) Shares A Year Ago You'd Have Earned 101% ReturnsWhile Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) shareholders are probably generally happy, the stock hasn't had...Is New 90 Day High Low • Dec 08New 90-day low: ₩9,900The company is down 9.0% from its price of ₩10,900 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: ₩120 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: ₩1.08b (up 8.9% from 3Q 2019). Net loss: ₩577.5m (loss narrowed 7.2% from 3Q 2019).Is New 90 Day High Low • Oct 08New 90-day high: ₩15,300The company is up 174% from its price of ₩5,580 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.Is New 90 Day High Low • Sep 22New 90-day high: ₩12,800The company is up 163% from its price of ₩4,860 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.공시 • Jun 20Jeonjinbio Co., Ltd. announced that it has received KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment ArmOn June 18, 2020, Jeonjinbio Co., Ltd. (KOSDAQ:A110020) closed the transaction.공시 • Jun 18Jeonjinbio Co., Ltd. announced that it expects to receive KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment Arm and other investorsJeonjinbio Co., Ltd. (KOSDAQ:A110020) announced a private placement of 7th series unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 3,500,000,000 on June 16, 2020. The bonds have a coupon rate of 1% and maturity date of June 18, 2023. The bonds are convertible into 702,106 common shares representing 14.64% stake at a conversion price of KRW 4,985 and the conversion period of the bonds will start from June 18, 2021 and end on May 18, 2023. The transaction will include participation from KB Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, Gicheol Oh for KRW 1,000,000,000, JooEun Seo for KRW 300,000,000 and Geun-bae Kim for KRW 200,000,000. The transaction has been approved by the board of directors of the company. The payment date and subscription date of the transaction is June 18, 2020. The bonds are subject to prohibition of exercise for 1 year and prohibition of division/merging.매출 및 비용 세부 내역Jeonjinbio가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A110020 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2614,421173,38542231 Dec 2513,694-1963,42643830 Sep 2514,6547283,04042930 Jun 2515,4519563,03439931 Mar 2517,0224,2453,21837031 Dec 2419,2734,3463,35936230 Sep 2419,9599783,57239530 Jun 2419,142-2013,79243031 Mar 2417,686-5,5503,84145531 Dec 2315,681-6,4403,93744830 Sep 2313,204-4,3273,91441930 Jun 2310,893-4,9053,75342531 Mar 239,055-2,9993,56040531 Dec 227,794-3,1133,37342230 Sep 225,899-2,5043,38439930 Jun 224,557-2,2283,37437131 Mar 223,457-2,4623,32841131 Dec 213,214-2,1083,71636430 Sep 213,496-3,6093,79337530 Jun 213,796-3,2753,69835231 Mar 213,910-3,8823,79434631 Dec 203,867-3,4183,40034530 Sep 204,732-1,6043,67735330 Jun 204,643-1,6483,75644731 Mar 204,426-1,3303,53241631 Dec 193,949-1,4623,19446530 Sep 192,230-3,4373,00853230 Jun 191,357-3,5792,58745831 Mar 191,243-3,4952,45242831 Dec 181,384-3,3992,50236130 Sep 182,216-3,6103,32525830 Jun 182,392-3,3663,28721931 Mar 182,792-3,1303,30220931 Dec 173,136-3,0413,44219230 Sep 172,645-2,6262,69818330 Jun 173,106-3,3253,49119831 Mar 172,895-3,6973,46123331 Dec 164,809-3,0744,43919631 Dec 152,018-2,9312,59737양질의 수익: A110020는 고품질 수익을 보유하고 있습니다.이익 마진 증가: A110020의 현재 순 이익률 (0.1%)은 지난해 (24.9%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A110020는 지난 5년 동안 흑자전환하며 연평균 39.2%의 수익 성장을 기록했습니다.성장 가속화: A110020은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: A110020은 지난 1년 동안 수익이 감소(-99.6%)하여 Chemicals 업계 평균(-3.5%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: A110020의 자본 수익률(0.1%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/25 17:05종가2026/06/25 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Jeonjinbio Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
분석 기사 • Mar 14We Think Jeonjinbio's (KOSDAQ:110020) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) strong earnings didn't offer...
Reported Earnings • May 19First quarter 2024 earnings released: ₩36.00 loss per share (vs ₩169 loss in 1Q 2023)First quarter 2024 results: ₩36.00 loss per share (improved from ₩169 loss in 1Q 2023). Revenue: ₩4.41b (up 84% from 1Q 2023). Net loss: ₩282.3m (loss narrowed 76% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.
Reported Earnings • Nov 14Third quarter 2020 earnings released: ₩120 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: ₩1.08b (up 8.9% from 3Q 2019). Net loss: ₩577.5m (loss narrowed 7.2% from 3Q 2019).
New Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.9b (US$9.68m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩14.9b market cap, or US$9.68m). Minor Risk Profit margins are more than 30% lower than last year (0.1% net profit margin).
Valuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₩2,450, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.
공시 • Mar 11Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,848, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 54% over the past three years.
분석 기사 • Nov 21Returns At Jeonjinbio (KOSDAQ:110020) Are On The Way UpIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
New Risk • Oct 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩24.9b market cap, or US$17.5m).
분석 기사 • Sep 03The Price Is Right For Jeonjinbio Co., Ltd. (KOSDAQ:110020) Even After Diving 28%Unfortunately for some shareholders, the Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has dived 28% in the last...
분석 기사 • Jul 24Returns On Capital Are Showing Encouraging Signs At Jeonjinbio (KOSDAQ:110020)There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,260, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 19% over the past three years.
New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩30.9b market cap, or US$22.7m).
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,630, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.
New Risk • May 23New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 25% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Market cap is less than US$100m (₩20.3b market cap, or US$14.8m).
분석 기사 • Mar 14We Think Jeonjinbio's (KOSDAQ:110020) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) strong earnings didn't offer...
공시 • Mar 06Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South Korea
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩2,885, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 48% over the past three years.
분석 기사 • Jan 07Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) Price In Tune With RevenuesWhen close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.6x...
New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩21.3b market cap, or US$14.5m).
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩24.5b market cap, or US$17.0m).
분석 기사 • Oct 25There's Been No Shortage Of Growth Recently For Jeonjinbio's (KOSDAQ:110020) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
공시 • Jun 15Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun.Dabin BNS Co., Ltd. agreed to acquire 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun for KRW 22 billion on October 13, 2023. The transaction is expected to close on November 24, 2023. As on November 24, 2023, the transaction is expected to close on December 15, 2023. The transaction is expected to complete on March 28, 2024. The transaction is expected to complete on May 9, 2024. The transaction is expected to complete on May 30, 2024. As of May 30, 2024, the transaction is expected to close on June 5, 2024. The transaction is expected to complete on June 07, 2024. As of June 7, 2024, the transaction is expected to close on June 13, 2024.Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun on June 13, 2024.
분석 기사 • Jun 07With A 38% Price Drop For Jeonjinbio Co., Ltd. (KOSDAQ:110020) You'll Still Get What You Pay ForThe Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has fared very poorly over the last month, falling by a...
New Risk • Jun 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩33.4b market cap, or US$24.4m).
Reported Earnings • May 19First quarter 2024 earnings released: ₩36.00 loss per share (vs ₩169 loss in 1Q 2023)First quarter 2024 results: ₩36.00 loss per share (improved from ₩169 loss in 1Q 2023). Revenue: ₩4.41b (up 84% from 1Q 2023). Net loss: ₩282.3m (loss narrowed 76% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.
공시 • May 09Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million.Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million. Security Name: Shares Security Type: Common Stock Securities Offered: 188,679 Price\Range: KRW 5300 Transaction Features: Subsequent Direct Listing
분석 기사 • Apr 03Shareholders Should Be Pleased With Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) PriceJeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) price-to-sales (or "P/S") ratio of 3.7x may look like a poor investment...
New Risk • Oct 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩63.6b market cap, or US$46.8m).
New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩40.4b market cap, or US$30.5m).
New Risk • Jul 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.4b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₩37.0b market cap, or US$29.3m).
분석 기사 • Apr 13Is Jeonjinbio (KOSDAQ:110020) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Mar 07New 90-day high: ₩12,700The company is up 2.0% from its price of ₩12,500 on 07 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period.
분석 기사 • Feb 19If You Had Bought Jeonjinbio (KOSDAQ:110020) Shares A Year Ago You'd Have Earned 101% ReturnsWhile Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) shareholders are probably generally happy, the stock hasn't had...
Is New 90 Day High Low • Dec 08New 90-day low: ₩9,900The company is down 9.0% from its price of ₩10,900 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: ₩120 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: ₩1.08b (up 8.9% from 3Q 2019). Net loss: ₩577.5m (loss narrowed 7.2% from 3Q 2019).
Is New 90 Day High Low • Oct 08New 90-day high: ₩15,300The company is up 174% from its price of ₩5,580 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.
Is New 90 Day High Low • Sep 22New 90-day high: ₩12,800The company is up 163% from its price of ₩4,860 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.
공시 • Jun 20Jeonjinbio Co., Ltd. announced that it has received KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment ArmOn June 18, 2020, Jeonjinbio Co., Ltd. (KOSDAQ:A110020) closed the transaction.
공시 • Jun 18Jeonjinbio Co., Ltd. announced that it expects to receive KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment Arm and other investorsJeonjinbio Co., Ltd. (KOSDAQ:A110020) announced a private placement of 7th series unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 3,500,000,000 on June 16, 2020. The bonds have a coupon rate of 1% and maturity date of June 18, 2023. The bonds are convertible into 702,106 common shares representing 14.64% stake at a conversion price of KRW 4,985 and the conversion period of the bonds will start from June 18, 2021 and end on May 18, 2023. The transaction will include participation from KB Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, Gicheol Oh for KRW 1,000,000,000, JooEun Seo for KRW 300,000,000 and Geun-bae Kim for KRW 200,000,000. The transaction has been approved by the board of directors of the company. The payment date and subscription date of the transaction is June 18, 2020. The bonds are subject to prohibition of exercise for 1 year and prohibition of division/merging.